Influence of preapheresis clinical factors on the efficiency of CD34+ cell collection by large-volume apheresis.
We evaluated 120 leukapheresis procedures (93 patients), in order to detect clinical factors that influence the efficiency of CD34+ collection using Cobe Spectra trade mark cell separators. Hematocrit was >27% and platelet count >30 000/microl in >95% of patients. Platelet transfusions were given if the postprocedure count was &<20 000/microl. Multiple regression analysis was used to analyze putative factors, and a predictive equation defined by stepwise regression modeling. The mean efficiency was 0.59 (s.d. 0.27). Sex (M>F; P=0.01), the volume processed (inversely; P=0.01) and CD34+ cell count (inversely; P=0.04) were associated with efficiency, whereas hematocrit, platelet or leukocyte count, catheter type and patient weight were not. The effect size for predictive factors was small (R(2)=0.21). Adverse events were limited to hypocalcemia. We conclude that female sex, volume processed and CD34+ cell count adversely influence the efficiency of CD34+ cell leukapheresis. However, the impact of volume and CD34+ cell count is small, and likely to be offset by the influence of these same factors on overall yield. Leukapheresis appears to be safe and efficient for autologous blood and marrow transplantation patients with hematocrit >27% and platelet count >30 000/microl.
Sarkodee-Adoo
C
C
University of Maryland School of Medicine, Greenebaum Cancer Center, Baltimore, MD, USA.
Taran
I
I
Guo
C
C
Buadi
F
F
Murthy
R
R
Cox
E
E
Lopez
R
R
Westphal
S
S
Shope
S
S
O'Connell
B
B
Wethers
L
L
Meisenberg
B
B
D018952:Antigens, CD34 / Q000097:blood*; D015704:CD4 Antigens / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006400:Hematocrit; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007937:Leukapheresis / Q000379:methods*; D008297:Male; D010976:Platelet Count; D011994:Recombinant Proteins; D015203:Reproducibility of Results; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome
D018952:Antigens, CD34; D015704:CD4 Antigens; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide